Frequent Mutation of Isocitrate Dehydrogenase<i>(IDH)1</i>and<i>IDH2</i>in Cholangiocarcinoma Identified Through Broad-Based Tumor GenotypingDarrell R. Borger, A. John Iafrate, Kenneth K. Tanabe et al.|The Oncologist|2011Cited by 724
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic CholangiocarcinomaDarrell R. Borger, Andrew X. Zhu, Lipika Goyal et al.|Clinical Cancer Research|2014Cited by 138
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir Fathi, Yi‐Bin Chen, Hossein Sadrzadeh et al.|Blood|2012Cited by 123
Isocitrate Dehydrogenase 1 (<i>IDH1</i>) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-HydroxyglutarateAmir T. Fathi, Darrell R. Borger, Hossein Sadrzadeh et al.|The Oncologist|2014Cited by 74
IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft ModelKatharine Yen, Fang Wang, René M. Lemieux et al.|Blood|2013Cited by 13